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Abstract
Background: Tumor microenvironment, which is largely affected by inflammatory cells, is a crucial
participant in the neoplastic process through promotion of cell proliferation, survival and migration.
We measured the effects of polymorphonuclear neutrophil (PMN) conditioned medium alone, and
supplemented with serine proteinase inhibitor α-1 antitrypsin (AAT) or its C-terminal fragment (C-
36 peptide), on cultured lung cancer cells.
Methods: Lung cancer HCC cells were grown in a regular medium or in a PMN-conditioned
medium in the presence or absence of AAT (0.5 mg/ml) or its C-36 peptide (0.06 mg/ml) for 24 h.
Cell proliferation, invasiveness and release of IL-8 and VEGF were analyzed by [3H]-thymidine
incorporation, Matrigel invasion and ELISA methods, respectively.
Results:  Cells exposed to PMN-conditioned medium show decreased proliferation and IL-8
release by 3.9-fold, p < 0.001 and 1.3-fold, p < 0.05, respectively, and increased invasiveness by 2-
fold (p < 0.001) compared to non-treated controls. In the presence of AAT, PMN-conditioned
medium loses its effects on cell proliferation, invasiveness and IL-8 release, whereas VEGF is up-
regulated by 3.7-fold (p < 0.001) compared to controls. Similarly, C-36 peptide abolishes the effects
of PMN-conditioned medium on cell invasiveness, but does not alter its effects on cell proliferation,
IL-8 and VEGF release. Direct HCC cell exposure to AAT enhances VEGF, but inhibits IL-8 release
by 1.7-fold (p < 0.001) and 1.4-fold (p < 0.01) respectively, and reduces proliferation 2.5-fold (p <
0.01). In contrast, C-36 peptide alone did not affect these parameters, but inhibited cell invasiveness
by 51.4% (p < 0.001), when compared with non-treated controls.
Conclusions: Our data provide evidence that neutrophil derived factors decrease lung cancer
HCC cell proliferation and IL-8 release, but increase cell invasiveness. These effects were found to
be modulated by exogenously present serine proteinase inhibitor, AAT, and its C-terminal
fragment, which points to a complexity of the relationships between tumor cell biological activities
and local microenvironment.
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Background
The relationship between inflammation, innate immunity
and cancer is widely accepted. Early in the neoplastic proc-
ess, inflammatory cells and their released molecular spe-
cies influence the growth, migration and differentiation of
all cell types in the tumor microenvironment, whereas
later in the tumorigenic process neoplastic cells also divert
inflammatory mechanisms, such as metalloproteinase
production, and chemokine/cytokine functions to favour
tumor spread and metastasis [1-3]. Human polymorpho-
nuclear neutrophils (PMN) comprise 50–70% of circulat-
ing leukocytes and induce inflammatory reactions that
can be either cytotoxic for tumour cells or promote
tumour growth and metastasis [4,5]. For example, animal
studies show that circulating neutrophils isolated from
tumor-bearing animals reduce the number of metastatic
foci in the lung. Other studies reveal that neutrophils
stimulate tumour cell attachment to endothelial monol-
ayers [6,7] and neutrophil-released cytokines, growth and
angiogenic factors enhance tumour growth and spread
[8]. Most of the neutrophil-induced tumour-promoting
effects are attributed to their abilities to release proteases.
Neutrophil degranulation results in the release of serine
proteases, such as elastase, cathepsin G and protease-3,
which may contribute to the activation of matrix metallo-
proteinases (MMPs) that mediate tumor cell invasiveness
[9-12]. Recently, Schwartz and co-workers found that neu-
trophil-secreted factors can activate pro-MMP-2, which is
important in ECM degradation and tumor cell invasion
[14]. It is now also apparent that tumor cells can be
sources of proteolytic enzymes themselves. For example,
some cells possess immunoreactive neutrophil elastase
[15], which is suggested to play a role in increasing tumor
cell invasiveness of surrounding tissue [16]. Levels of
immunoreactive neutrophil elastase in tumour extracts
are reported to be an independent prognostic factor for
patients with breast cancer and non-small cell lung cancer
[17-19].
A large number of studies support the notion that pro-
teases play an important role in the progression of malig-
nant tumors. Therefore, the expression of proteinase
inhibitors is considered to be an antimalignant event [20].
Alpha-1 antitrypsin (AAT), a major inhibitor of human
serine proteases in serum, is produced mainly by the liver,
but also by extrahepatic cells, including neutrophils and
certain cancer cells [21,22]. AAT is an acute phase protein
and its concentration rises up to 3–4-fold above normal
during acute inflammation [23]. Several types of cancer,
including non-small cell lung adenocarcinoma, have been
associated with increased serum levels of AAT [20,24].
Clinical studies have shown that high circulating levels of
AAT directly correlate with tumour progression [24-26].
Recently we also found that plasma levels of AAT are sig-
nificantly elevated in lung cancer patients and, particu-
larly in cases with metastases [27]. The role of AAT is
poorly understood in tumor diseases although it is sug-
gested that it can inhibit tumor cell growth and invasion,
in vitro [28]. Moreover, not only the native, inhibitory
form of AAT, but also conformationally modified, non-
inhibitory forms are suggested to play a role in modulat-
ing tumour growth and invasiveness. For example,
Kataoka and co-workers have shown that the C-terminal
fragment of AAT can enhance the growth and invasiveness
of human pancreas adenocarcinoma cells, in vivo [29].
Our in vitro studies revealed that the C-terminal fragment
of AAT, corresponding to amino acid sequence 358–396
(C-36 peptide), induces breast tumour cell proliferation
and invasiveness [30]. Recently we found that C-36 pep-
tide induces neutrophil chemotaxis, adhesion, degranula-
tion and superoxide generation, in vitro [31], which we
propose may indirectly affect tumor cell biological activi-
ties, in vivo. Together these findings prompted us to design
an experimental model in vitro that would allow us to
evaluate how neutrophil-derived products themselves and
in combination with exogenously added native AAT or its
C-36 peptide influence lung cancer HCC cell growth,
invasion and metastatic properties.
Results
HCC cell proliferation
To examine the effect of the degranulated PMN-condi-
tioned media alone or supplemented with exogenously
added native AAT (0.5 mg/ml) or its C-36 peptide (0.06
mg/ml) on lung cancer HCC cell proliferation, we meas-
ured DNA biosynthesis using a [3H]-thymidine incorpora-
tion assay (Fig. 1). HCC cells cultured in PMN-
conditioned medium for 24 h decrease proliferation by
3.9-fold, (p < 0.001), while under the same experimental
conditions cells exposed to PMN-conditioned medium
supplemented with native AAT show no changes in prolif-
eration compared to control cells cultured in a regular
media. HCC cells exposed directly to native AAT decrease
[3H] thymidine incorporation by 2.5-fold, (p < 0.01)
compared to control cells cultured in a regular medium.
Thus, our data show that both PMN-conditioned medium
and AAT loose their inhibitory effects on cancer cell pro-
liferation when used in combination. Under the same
experimental conditions, the C-36 peptide of AAT added
either directly to HCC cells or as a supplement with PMN-
conditioned medium did not exert any significant effects
on HCC cell proliferation relative to controls (Fig. 1).
HCC cell invasiveness
To characterize lung cancer cell properties after their expo-
sure to PMN-conditioned medium with and without
added AAT or its C-36 peptide, we performed cell inva-
siveness assays. As illustrated in Fig. 2 and Table 1, cells
cultured in a PMN-conditioned medium show markedly
increased cell invasiveness (by 56.8%, p < 0.001)Cancer Cell International 2004, 4:7 http://www.cancerci.com/content/4/1/7
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compared to controls. When PMN-conditioned medium
is supplemented with native AAT or its C-36 peptide, its
effects on cancer cell invasiveness are diminished by
41.5%, and 77%, (p < 0.001), respectively, compared to
PMN medium alone. It must be pointed out that HCC
cells cultured in a regular medium in the presence of C-36
peptide decreased cell invasion by 51.4%, (p < 0.001),
while native AAT showed slight, but not significant up-
regulation of cell invasiveness, compared to controls.
Together these data show that native AAT as well as its C-
36 peptide abolish the capacity of PMN-conditioned
medium to stimulate HCC cell invasiveness.
Release of Vascular Endothelial Growth Factor (VEGF) and 
interleukin-8 (IL-8)
Vascular endothelial growth factor (VEGF) and chemok-
ine IL-8 are factors produced by tumor cells as well as by
neutrophils [32-34], and are known to correlate with lung
cancer angiogenesis in vivo [35]. We analysed for VEGF
and IL-8 released by HCC cells alone or cultured in PMN-
conditioned medium with and without added AAT or C-
36 peptide for 24 h (Fig. 3 and 4). As shown in Fig 3, AAT
increases VEGF release by 1.7-fold, p < 0.001, and inhibits
IL-8 by 1.4-fold, p < 0.01, relative to control cells. Under
the same experimental conditions, cancer cells cultured in
a PMN-conditioned medium supplemented with AAT
increase VEGF and IL-8 release by 3.7-fold, p < 0.001 and
1.6-fold, p < 0.01, respectively, compared to PMN-condi-
tion medium alone. In addition, HCC cells in a PMN-con-
ditioned medium show a slight (~27%), but not
significant, decrease in VEGF levels compared to cells
grown in regular medium. It must be noted that C-36 pep-
tide had no influence on VEGF and IL-8 levels under any
experimental conditions used (data not shown).
Enzymatic activity in PMN-conditioned medium
Neutrophil degranulation results in a large release of pro-
teases, and to verify this we monitored proteolytic activity
in PMN-conditioned medium by zymography, an electro-
phoretic technique used for the qualitative evaluation of
proteases. As illustrated in Fig. 5 and 6 line-1, PMN-con-
ditioned medium reveals a specific pattern of gelatinolytic
and caseinolytic activity at a position between 72 and 180
kDa, which most likely represents neutrophil collagenase
(MMP-8) (75 kDa), gelatinase A (MMP-2) (72 kDa), gela-
tinase B (MMP-9) (92 kDa) and several MT-MMPs, such
as MT-MMP-2, -5 (72–75 kDa). Lung cancer cells grown
in regular medium (Fig. 5 and 6, line-7) or treated with
AAT and C-36 peptide show no gelatinolytic (Fig. 5, lines
6, 5) and caseinolytic activity (Fig. 6, lines-5, 3). PMN-
conditioned medium incubated with HCC cells for 24 h
manifested a decrease in certain enzymatic activities (Fig.
5, line 4, Fig. 6, line 6) compared to PMN media alone
(Fig 5 and 6, line-1). However, no further changes in enzy-
matic activity profiles were observed when HCC cells were
[3H]Thymidine incorporation assay Figure 1
[3H]Thymidine incorporation assay. The HCC cells were 
exposed to AAT (0.5 mg/ml) or its C-36 peptide (0.06 mg/
ml) in a regular medium or in a PMN-conditioned medium 
for 20 h following addition of [3H] thymidine for 4 h. Each bar 
represents mean ± standard deviation from three separate 
experiments with three repeats in each. *** p < 0.001, ** p < 
0.01.
HCC cell invasiveness after exposure to PMN-conditioned  media, AAT or C-36 peptide separately and in combinations Figure 2
HCC cell invasiveness after exposure to PMN-conditioned 
media, AAT or C-36 peptide separately and in combinations. 
HCC cells cultured in a regular medium (I) and in a PMN-
conditioned medium (II) alone or supplemented with AAT or 
C-36 peptide (this figure represents one of three independ-
ent experiments).Cancer Cell International 2004, 4:7 http://www.cancerci.com/content/4/1/7
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grown in PMN-conditioned medium supplemented with
native AAT (Fig. 5, line 3 and 6 line-5) or C-36 peptide
(Fig 5 and 6, line-2).
Molecular profile of AAT in HCC cell culture supernatants
Cell culture supernatants collected from HCC cells cul-
tured in a regular medium or in PMN-conditioned
medium with and without addition of AAT were analysed
for AAT by 7.5% SDS-PAGE followed by immunoblotting
using polyclonal antibody against human AAT. As shown
in Fig. 7, line-2, AAT added to HCC cells was unchanged
in amount and form compared to native AAT alone (Fig.
7, line-5), whereas AAT added as a supplement into PMN-
conditioned medium is altered in the distribution of its
forms: in addition to monomeric AAT, a complexed form
of AAT can be detected (Fig. 7, lane-4).
Discussion
Local and systemic inflammatory mediators derived by
tumor-associated PMN and tumor cells are suggested to
play a role in the development of lung tumors [36,37].
Different studies have reported an increase of proteolytic
activity in cancer and have suggested a role of proteases in
tumor progression and metastasis [38-40]. For example,
Guner and co-workers have shown that the plasma con-
centration of elastase in patients with malignant lung
carcinoma is 10-fold higher compared to benign lesions
Table 1: Quantitative evaluation of HCC cell invasiveness (migrated cells/per view, in ten randomly selected fields).
Stimulus HCC cells in a regular medium HCC cells in PMN-conditioned medium
mean♠) SEM mean SEM
Control (medium) 27.8 ± 0.85 43.6*** ± 1.6
AAT (0.5 mg/ml) 32.7 ± 2.1 25.5*** ± 1.99
C-36 (0.06 mg/ml) 13.5*** ± 1.5 10.0*** ± 0.86
♠ mean and standard error of 3 independent experiments; *** -p < 0.001
VEGF release from HCC cells alone or exposed to PMN- conditioned medium with and without addition of AAT Figure 3
VEGF release from HCC cells alone or exposed to PMN-
conditioned medium with and without addition of AAT. Each 
bar represents the mean ± standard deviation of six repeats 
from two separate experiments with three repeats in each. 
*** p< 0.001
HCC
cells+AAT
HCC cells+[PMN-
media+AAT]
HCC cells + 
PMN-media
HCC cell 
control
IL-8 release from HCC cells alone or exposed to PMN-con- ditioned medium with and without addition of AAT Figure 4
IL-8 release from HCC cells alone or exposed to PMN-con-
ditioned medium with and without addition of AAT. Each bar 
represents the mean ± standard deviation of six repeats from 
two separate experiments with three repeats in each. ** p < 
0.01, * p < 0.05.Cancer Cell International 2004, 4:7 http://www.cancerci.com/content/4/1/7
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of the lungs [41]. An increased concentration of
neutrophil elastase is found to be closely associated with
progression of non-small cell lung cancer (NSCL). In par-
allel, an increase in levels of proteinase inhibitors, such as
AAT, has also been reported in tumor cases, including
lung tumors. These elevated levels of proteinase inhibitors
are attributed to the inflammatory reactions accompany-
ing the tumorigenesis [42,43].
PMN, the most abundant circulating blood leukocytes,
are potent effectors of inflammation and release a wide
profile of serine and metalloproteinases [44]. Infiltration
of tumors with PMN is associated with a favourable
prognosis in some studies in humans, however for indi-
vidual patients there is no predictable relationship
between PMN infiltration and cancer prognosis [45,46].
Thus, in the present study we aimed to investigate how
degranulated neutrophil-conditioned medium alone and
supplemented with the serine proteinase inhibitor, AAT,
or its C-terminal peptide (C-36), affects functional
activities of a non-small cell lung adenocarcinoma cell
line (HCC), in vitro.
We found that PMN-conditioned medium expresses mul-
tiple effects on lung cancer HCC cell functional activities
(decreases in cell proliferation and IL-8 release and stimu-
lation of cell invasion through the ECM membrane), but
has no significant effects on VEGF release. These dual neu-
trophil activities toward cancer cells have been described
by other investigators. It has been suggested that through
the release of cytokines, chlorinated oxidants and
defensins, neutrophils may cause direct tumor killing
[47,48] while in parallel, through release of serine
proteinases and MMPs, breakdown of basement mem-
branes and ECM and increase in tumor invasiveness are
promoted [49]. Our findings that PMN-conditioned
medium decreases HCC cancer cell proliferation and IL-8
release, but increases invasiveness, in part support the
hypothesis that neutrophils can both, inhibit and pro-
mote tumor cell growth and invasiveness. In parallel
experiments, we found that PMN-conditioned medium
supplemented with AAT loses its effects on HCC cell inva-
sion, proliferation and IL-8 release, but enhances VEGF. In
contrast, C-36 peptide added to PMN-conditioned
medium abolished the effects of medium on cell invasive-
ness, but had no significant influence on medium effects
on cell proliferation, IL-8 and VEGF release.
Effects of PMN-conditioned medium alone and supplemented  with AAT or C-36 peptide on HCC cell gelatinolytic activity Figure 5
Effects of PMN-conditioned medium alone and supplemented 
with AAT or C-36 peptide on HCC cell gelatinolytic activity. 
Lane 1-PMN-conditioned medium alone; lanes 2 and 3, PMN-
conditioned medium supplemented with C-36 peptide and 
AAT, respectively; and incubated with cancer cells for 24 h, 
lane 4-PMN-conditioned medium incubated with HCC cells 
alone; lanes 5 and 6 – HCC cells exposed to C-36 peptide 
and AAT, respectively, in a regular medium; 7-HCC cells 
alone. This figure represents 1 of 3 separate experiments 
performed under the same experimental conditions.
1 2 3 4 567 M
Effects of PMN-conditioned medium alone and supplemented  with AAT or C-36 peptide on HCC cell caseinolytic activity Figure 6
Effects of PMN-conditioned medium alone and supplemented 
with AAT or C-36 peptide on HCC cell caseinolytic activity. 
Lane 1-PMN-conditioned medium alone; lanes 2-PMN-condi-
tioned medium supplemented with C-36 peptide and incu-
bated with HCC cells for 24 h, line 3-HCC cells exposed to 
C-36; lane 4-; PMN-conditioned medium supplemented with 
AAT and incubated with HCC cells for 24 h, lane 5-HCC 
cells exposed to AAT; lane 6-PMN-conditioned medium 
incubated with HCC cells; lane 7-HCC cells alone. This figure 
represents 1 of 3 separate experiments performed under the 
same experimental conditions.
1          2     3    4         5   6    7     MCancer Cell International 2004, 4:7 http://www.cancerci.com/content/4/1/7
Page 6 of 10
(page number not for citation purposes)
The major function of AAT is to inhibit neutrophil derived
serine proteases, particularly neutrophil elastase [50]. A
local increase of proteinases and PMN elastase-AAT
complexes has been demonstrated in bronchoalveolar
lavage from patients with lung cancer [51]. AAT is also
known to interact with other components of degranu-
lated-PMN. For example, AAT binds to defensins and neu-
tralizes their effects on cell cytotoxicity and migration
[52]. In our in vitro model, AAT added to degranulated
PMN-conditioned medium occurs in a complexed form.
Thus, the modulating effects of AAT on PMN-medium
activities toward HCC cancer cells can be attributed to
AAT alone, but also to its interaction(s) with components
of the medium. Verification of the effects of AAT on sepa-
rate components released by degranulated PMN needs
further investigations.
It is important to point out that AAT alone as well as in
combination with PMN-conditioned medium induced
VEGF release from HCC cells. VEGF is one of the most
potent angiogenic molecules, regulating both angiogen-
esis and vascular permeability, and hence promotes
tumor progression and development in NSCLC [53].
Many compounds, including anti-VEGF antibody and
anti-VEGF receptor antibody have been developed as
VEGF inhibitors and these compounds were reported to
inhibit growth of a wide variety of tumor cell lines in vitro
and in animal models, in vivo [54]. Therefore, our in vitro
findings that AAT expresses potent effects on VEGF release
allow classify AAT as a tumor promoter. Contrary data
exist for a relationship between the levels of AAT and can-
cer advancement. Some investigators propose that AAT
plays a protective role in tumorogenesis. For example,
Finlay and co-workers showed that AAT might be directly
involved in breast cancer progression by acting as a tumor
suppressor [55]. Yavelow and co-workers have shown that
AAT inhibits human breast cancer cells MCF-7 growth
[56] and AAT was also shown to block the activation of
pro MMP-2 and tumor cell invasion [11]. However,
immunohistochemical studies revealed that patients with
AAT-positive colon, gastric and lung adenocarcinomas
had a worse prognosis than AAT-negative ones [57-59].
Together these findings suggest that AAT may play multi-
ple roles in cancerogenesis in vivo, in addition to its role
as proteinase inhibitor.
During tumor progression, inflammatory cells produce
large amounts of IL-8, an autocrine growth factor [53,60].
Levels of IL-8 have also been shown to correlate with lung
cancer angiogenesis. Current knowledge of the degranula-
tion process of neutrophils in vitro suggests that the chem-
okine IL-8 promotes rapid release of all neutrophil
granular stores after cell exposure to cytoskeleton-disrupt-
ing agents [61]. In the present study, we found that the
amount of IL-8 released by HCC can be reduced by AAT or
PMN-conditioned medium alone, whereas these inhibi-
tory effects are abolished when AAT and PMN-condi-
tioned media are added together. Based on our findings,
we hypothesize that IL-8 and other angiogenic factors
released from HCC cells are regulated by PMN compo-
nents, which may potentially initiate tumor cell activities
or induce anti-tumor responses dependent on the tumor
cell microenvironment.
AAT is the main inhibitor of neutrophil elastase and pro-
teinase 3 [62] and it has been reported that an imbalance
between AAT and neutrophil elastase may predispose to
lung cancer development [63]. Patients who carry the
deficiency allele of AAT have a significantly higher risk of
developing squamous cell or bronchoalveolar carcinoma
of the lungs [64]. On the other hand it was reported that
strong expression of AAT in lung adenocarcinoma corre-
lates with poor prognosis [65], although it was not shown
whether the inhibitory activity of AAT was normal and
HCC cell culture medium alone and in the presence of AAT  studied by Western blot analysis Figure 7
HCC cell culture medium alone and in the presence of AAT 
studied by Western blot analysis. Cell culture supernatants 
were applied to 10% SDS-PAGE and immunoblotted with 
polyclonal antibody against AAT. M, molecular size markers 
(myosin-205 000, β-galactosidase-123 000, bovine serum 
albumin-79 000, carbonic anhydrase-45 700), lane 1-HCC 
cells alone, lane 2-HCC cells stimulated with AAT, lanes 3 
and 4-HCC cells cultured in PMN-conditioned medium alone 
and supplemented with AAT, respectively lane 5-ATT done. 
The arrow indicates complexed AAT. The AAT profile 
shown in this figure represents one of three similar 
experiments.
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whether elastase levels were high among this group of
patients. Moreover, AAT is a good substrate for MMPs:
neutrophil collagenase, gelatinase-B, stromelysin-1 and -
3, and matrilysin can effectively cleave AAT [66-69]. The
cleavages by these MMPs occurs at peptide bonds within
AAT active site loop, resulting in a generation of cleaved
forms of AAT. Comparative proteome analysis performed
to identify protein alterations in plasma of prostate, lung
and breast-cancer patients showed significant elevation of
AAT and its N-terminal fragment [70], which points to a
role for different molecular forms of AAT in cancer pro-
gression. Recent studies provide evidence that the C-ter-
minal fragment of AAT may enhance tumor growth and
invasiveness in vitro and in vivo [29,30]. We found that the
C-36 peptide displays striking concentration-dependent
pro-inflammatory effects on human neutrophils, includ-
ing induction of neutrophil chemotaxis, adhesion,
degranulation and superoxide generation [31]. Interest-
ingly, in our HCC cancer cell model, C-36 peptide
reduced HCC cell invasiveness and also abolished PMN-
conditioned medium-induced cell invasiveness, whereas
there were no significant effects on other parameters
measured, such as cell proliferation, VEGF and IL-8
release.
Conclusions
Our data show that AAT in various molecular forms
expresses differential effects on lung tumour cell
responses and provide an experimental evidence for com-
plexity in the interactions of neutrophil-released molecu-
lar species and lung cancer cells.
Materials and methods
AAT and its C-terminal peptide
Native, purified human plasma AAT was purchased from
the Clinical Chemistry Department (UMAS, Malmö). The
quality of AAT preparations was confirmed by 7.5% SDS-
PAGE and determination of anti-elastase activity as
described by Gaillard et al. [71]. Synthetic C-terminal frag-
ment of AAT (C-36, corresponding to residues 359–394)
was obtained from Saveen, Biotech AB (Denmark) and
was greater than 98% purity. The C-36 peptide was pre-
pared in sterile, endotoxin-free Tris buffered saline (0.015
M Tris, pH 7.4 containing 0.15 M NaCl) just before use.
The endotoxin content in AAT was tested by quantitative
E-TOXATE Assay (Sigma, USA). According to interna-
tional standards no more than 0.08 enzyme U/ml of
endotoxin is allowed to be present in AAT solutions [72].
In our experimental model we used AAT preparation with
endotoxin levels below 0.05 enzyme U/ml. If necessary,
AAT samples were purified using Detoxi-Gel™ endotoxin
removing gel (Pierce, Rockford, IL, USA) according to the
manufacturers recommendations.
Neutrophil isolation
Neutrophils were isolated from the peripheral blood of
healthy donors using Polymorphprep™ (Axis-Shield PoC
AS, Oslo, Norway) according to the manufacturers recom-
mendations. Neutrophils were harvested as the lower cel-
lular band above the red cell pellet. Residual erythrocytes
were removed by a hypotonic lysis using ice cold 0.2%
NaCl (w/v) for 30 s, followed addition of an equal vol-
ume of 1.6% NaCl to restore isotonicity. The neutrophil
purity was typically 90% as determined by an AC900EO
AutoCounter (Swelab Instruments, Sweden) and cell via-
bility exceeded 95% according to trypan blue staining.
Preparation of PMN-conditioned medium
PMN-conditioned medium was prepared by degranulat-
ing neutrophils (5 × 106 cells/ml) according to Videm and
Strand [72]. Briefly, isolated neutrophils were incubated
on a shaker for 1 h at 37°C and immediately after on ice
for 3 min, and centrifuged at 240 × g for 10 min at 4°C.
Supernatants were collected and analyzed for the cytokine
release and enzyme activity.
Cell culture
Human non-small cell lung carcinoma (HCC) cells were
established from the lung of 54-year old women with
non-small cell lung the adenocarcinoma type (DSMC No.
ACC 534). The cells were routinely grown at 37°C in a
humid air containing 5% CO2, in 125-cm2 flasks in RPMI-
1640 medium, supplemented with 10% FBS, 100 IU/ml
penicillin, and 100 µg/ml streptomycin. Medium was
changed every 2–3 days. Prior to experiments HCC cells
were seeded into 12-wells plates at a density of 3 × 105
cells/ml, and cultured until confluent. After, cells were
washed and a serum-free medium containing test sub-
stances was added for 24 h. Two sets of experiments were
designed: the first, in which HCC cells were exposed to
native AAT (0.5 mg/ml) or C-36 peptide (0.06 mg/ml) in
a RPMI-1640 and the second, in which the cells were cul-
tured in PMN-conditioned medium alone or supple-
mented with native AAT or C-36 peptide.
[3H] Thymidine incorporation assay
HCC cells were incubated with test substances for 20 h.
[3H] Thymidine was then added (0.2 µCi/ml) for a further
4 h at 37°C. The medium was then aspirated, the cells
were washed twice with 0.5 M NaCl and incubated for 5
min with 5% trichloroacetic acid. The cells were then
washed with distilled water, dissolved in 1 ml 0.5 M
NaOH, neutralised with 200 µl HCl and radioactivity
determined in a β-counter (Packard 300CD liquid scintil-
lation spectrometer; Packard Instruments). Protein con-
centration in cell lysates was determined by the Lowry
method using HSA as a standard.Cancer Cell International 2004, 4:7 http://www.cancerci.com/content/4/1/7
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Matrigel invasion assay
Cell invasion assay was performed in an invasion cham-
ber, a 24-well tissue culture plate with 12 inserts. The
inserts contain an 8 µm pore size polycarbonate filters
over which is placed a thin layer of ECMatrix™. HCC cells
were suspended in a serum free medium containing 1 ×
106 cells/ml alone or together with test substances. Each
suspension was added to the upper chamber of an ECM
Invasion system. Medium containing 10% of fetal bovine
serum (FBS), serving as a chemoattractant, was added to
the lower chamber. The chambers were incubated at 37°C
in 5% CO2 for 24 h. Invasive cells were stained and
counted using microscope (Olympus BX41, PC program
Olympus MicroImage) at a 100 × magnification. The
number of cells per field, from 10 randomly selected
fields, are presented.
Enzyme activity assay
HCC cells were cultured alone or stimulated with test sub-
stances for 24 h. Cell free supernatants were then analysed
by zymography using 10% and 12% Tris-Glycine gels con-
taining 0.1% gelatin or β-casein, respectively (NOVEX,
Invitrogen Life Technologies, UK). Briefly, supernatants
were diluted in a sample buffer and separated by electro-
phoresis at 125 V for 90 min. The gels were then renatured
and developed over night in a developing buffer (NOVEX,
Invitrogen Life Technologies, UK) at 37°C. After washing,
the gels were stained with Coomassie Blue R-250.
Proteases that can utilize casein or gelatine as a substrate
showed up as clear zones in the gels.
Endothelial growth factor (VEGF) and IL-8 analysis
HCC cell supernatants were analysed for the VEGF and IL-
8 levels by using commercially available quantitative
ELISA kits (R&D systems, Minneapolis, USA) according to
manufacturers instructions. The lowest detectable concen-
tration for VEGF and IL-8 was 15.6 pg/ml and 10 pg/ml,
respectively.
Immunoblotting
HCC cells supernatants were analysed by 10% SDS-PAGE
gels and when transferred to a polivinylidene fluoride
(PVDF) membrane (Millipore, Millipore Corporation,
Bedford, MA 01730) using a semi-dry immunoblot trans-
fer system. The blot was visualised using polyclonal rabbit
antibody to human AAT (1:500) (DAKO, A/S, Denmark),
secondary horseradish peroxidase-conjugated swine anti-
rabbit antibody (1:800) (DAKO, A/S, Denmark) and per-
oxidase substrate, DAB (3,3-diaminobenzidine tetrahy-
drochloride) (Sigma, USA).
Statistics
The differences in the means of experimental results were
analysed for their statistical significance with the one-way
ANOVA combined with a multiple-comparisons
procedure (Scheffe multiple range test), with an overall
significance level of α = 0.05. Statistical Package (SPSS for
Windows, release 11.0) was used for the statistical
calculations.
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